ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sanofi will pay San Diego-based Retrophin $245 million for its pediatric disease priority review voucher. PRVs, which can speed up the review of a New Drug Application, were introduced by FDA to encourage development of drugs for rare and neglected pediatric diseases. Retrophin received its PRV in March with FDA’s approval of Cholbam, a treatment for kids and adults with bile acid synthesis disorders caused by single-enzyme defects. Last year, Regeneron paid BioMarin $67.5 million for a PRV; Regeneron and Sanofi later used it to shave four months off the review time for their cholesterol-lowering drug alirocumab. Sanofi isn’t saying how it plans to use the Retrophin PRV.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter